このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Feasibility Study of Blood Biomarker Identification in Cervical Cancer (CLARITY)

2026年8月31日 更新者:Queensland Centre for Gynaecological Cancer

Feasibility Study of Blood Biomarker Identification in Cervical Cancer: Performance of Cell-free DNA Versus Extracellular Vesicles

This study aims to explore whether a simple blood test can be used to help detect and monitor cervical cancer. The investigators are studying tiny fragments and particles found in blood, called cell-free DNA (cfDNA) and extracellular vesicles (EVs), to determine whether these can act as early warning signs (biomarkers) of cervical cancer.

Cell-free DNA (cfDNA) refers to tiny fragments of genetic material (DNA) that are naturally released from cells into the bloodstream when cells die or renew. Cell-free DNA circulates naturally in the blood. In people with cancer, some of the cfDNA originates from cancer cells; this component is called circulating tumour DNA (ctDNA). Analysis of cfDNA can detect signs of cancer, such as specific genetic changes or pieces of viral DNA, including human papillomavirus (HPV) DNA, without requiring removal of tissue from the cervix.

Extracellular vesicles (EVs) are very small "packages" released by cells into the blood and other body fluids. EVs carry messages between cells and contain important information such as proteins, fats, and genetic material, including RNA. In cancer, tumour cells release EVs that reflect tumour behaviour and activity. Analysis of EVs can provide information about cancer growth and response to treatment.

Together, cfDNA and EVs can act as tiny messengers or "fingerprints" of biological processes occurring inside the body. Analysis of cfDNA and EVs in blood samples may support the development of a simple, less invasive, more comfortable, and more accessible approach to detecting and monitoring cervical cancer compared with current screening and diagnostic methods. A blood test could also assist doctors in monitoring treatment response or detecting early signs of recurrence without requiring a surgical biopsy.

The expected outcomes of this study are to identify specific patterns or "signatures" in extracellular vesicles (EVs) and cell-free DNA (cfDNA) found in blood samples. These signatures could help to:

Detect cervical cancer earlier, before symptoms appear or the disease progresses.

Monitor treatment response in real time without the need for invasive tests. Predict whether cervical cancer might recur or spread after treatment. Support more personalised care by helping doctors select the most suitable treatment for each participant.

調査の概要

詳細な説明

This study is an open-label, prospective, experimental study of patients with cervical cancer. The primary aim is to evaluate the feasibility, clinical utility, and analytical performance of extracellular vesicles (EVs) and cell-free DNA (cfDNA) as minimally invasive, blood-based biomarkers for the early detection, treatment monitoring, and post-treatment surveillance of cervical cancer, with the potential to inform future screening and therapeutic strategies.

Cervical cancer continues to impose significant physical, emotional, and financial burdens on women worldwide. Despite advances in prevention and treatment, a critical need remains for more effective, non-invasive tools to support early detection, monitor treatment response, and guide clinical decision-making. As the field of cervical cancer diagnosis evolves, interest is growing in the use of blood-based biomarkers, particularly extracellular vesicles (EVs) and cell-free DNA (cfDNA), to improve patient care.

This study aims to evaluate the potential of EVs and cfDNA as minimally invasive biomarkers in the management of cervical cancer. Analysis of EVs and cfDNA is intended to provide deeper insights into the roles of these biomarkers in tumour development, progression, and intercellular communication. The anticipated outcomes include the identification of EV- and cfDNA-based signatures that can:

Facilitate earlier detection of cervical cancer. Enable real-time monitoring of treatment response. Predict recurrence and disease progression. Support the development of personalised therapeutic strategies.

By generating preliminary comparative data on the diagnostic accuracy of EVs and cfDNA, this study will provide a critical foundation for future large-scale investigations. The study is intended to contribute to the development of a novel, blood-based screening and monitoring tool that could enable earlier intervention and improve long-term outcomes.

A reliable, non-invasive test could also provide a more accessible and acceptable alternative to current cervical screening methods, particularly for women who face cultural, systemic, or personal barriers to participation. This is especially important for under-screened populations, including Aboriginal and Torres Strait Islander women and culturally diverse communities.

Ultimately, this research is expected to advance understanding of the biological role of EVs and cfDNA in cervical cancer pathogenesis and progression. The research supports the development of clinically effective, personalised diagnostic tools that may improve outcomes, reduce healthcare costs, contribute to Australia's national strategy to eliminate cervical cancer as a public health issue, and address persistent inequities in access to care.

Study Intervention

This prospective cohort study will enrol 100 patients with stage IA to IVB cervical cancer who are undergoing either primary surgical treatment, radiotherapy (RT), or chemoradiotherapy (CRT).

The study intervention involves the collection of approximately 40 mL of blood at baseline, following the initial diagnosis of cervical cancer, for the analysis of cell-free DNA, extracellular vesicles, and germline DNA. Additional blood samples of the same volume will be collected at two subsequent time points: at 8 weeks following surgery or completion of chemoradiotherapy (CRT), and at 6 months post-baseline.

In addition, quality-of-life questionnaires will be completed by participants at the following time points:

First time point: Baseline: For participants undergoing primary surgery, baseline is the date of surgery. For participants undergoing definitive radiotherapy or chemoradiotherapy, baseline is the date of the first radiation dose. Baseline assessments can be performed up to 30 days before the date of surgery or up to 30 days before the first radiation dose.

Second time point: Immediately after completion of radiotherapy or chemoradiotherapy (+14 days), or 8 weeks after surgery (±14 days).

Third time point: 6 months post-baseline (±14 days). Follow-up (24 Months)

Participant disease status will be recorded at 24 months (±30 days) through review of participants' medical records.

In accordance with current European Society for Medical Oncology (ESMO) guidelines, patients diagnosed with early-stage invasive cervical cancer, such as FIGO stage IA to IB2 and selected IIA1, typically undergo primary surgical treatment, including radical hysterectomy or simple hysterectomy. For these patients, the second blood collection will occur at 8 weeks post-surgery (±14 days).

For patients with locally advanced cervical cancer (LACC), for whom primary surgery is not recommended because of poor outcomes or increased morbidity associated with combined treatments, such as FIGO stages IB3, IIA2, IIB, and IIIA-IIIB, the preferred or definitive treatment is concurrent chemoradiotherapy (CRT) followed by internal radiation (brachytherapy). In these cases, the second blood sample will be collected at the end of treatment (+14 days).

研究の種類

観察的

入学 (推定)

100

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Queensland
      • Brisbane、Queensland、オーストラリア、4029
        • 募集
        • Royal Brisbane and Women's Hospital
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Kristen Moloney

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

100 patients with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b).

説明

Inclusion Criteria:

  • Females, over 18 years, with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b)
  • Undergo intensive primary surgical treatment, radiotherapy (RT) or chemoradiotherapy (CRT).
  • Signed written informed consent

Exclusion Criteria:

  • Unable to provide informed consent
  • Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
  • Prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Patients with Cervical Cancer
Patients with FIGO stage IA-IVB cervical cancer undergoing standard-of-care primary surgery, radiotherapy, or chemoradiotherapy. Treatment is determined by the participant's treating clinical team and is not assigned by the study protocol. Participants will undergo serial blood collection for cfDNA and extracellular vesicle analyses, complete patient-reported outcome and quality-of-life questionnaires, and have disease status assessed through medical record review. Archival tumour tissue obtained during routine diagnostic biopsy or surgery will also be retrieved where available for translational analyses.
Approximately 40 mL of blood will be collected at baseline, approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy, and 6 months (±14 days) post-baseline. Blood samples will be processed for isolation and analysis of cell-free DNA (cfDNA), extracellular vesicles (EVs), and germline DNA.
他の名前:
  • 生体標本の収集
  • Peripheral blood collection
Blood-derived cell-free DNA (cfDNA) and extracellular vesicles (EVs) will be isolated and characterised using prespecified laboratory methods. cfDNA will be quantified, quality assessed, and may undergo sequencing. EVs will be characterised using methods including nanoparticle tracking analysis, transmission electron microscopy, western blotting, proteomics, and miRNA sequencing. Biomarker profiles will be evaluated in relation to disease stage, treatment response, and disease outcomes.
Participants will complete patient-reported outcome and quality-of-life questionnaires at baseline, approximately 8 weeks after surgery or completion of radiotherapy/chemoradiotherapy, and 6 months post-baseline. Assessments include the FACT-Cx, EQ-5D-5L, and self-reported lower-extremity lymphoedema questionnaires.
Formalin-fixed paraffin-embedded (FFPE) tumour tissue obtained during routine diagnostic biopsy or surgery will be retrieved from pathology laboratories where available. No research-specific tumour biopsy or surgery will be performed. Tumour tissue may undergo DNA extraction and sequencing for comparison with blood-derived DNA and other prespecified translational analyses.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of participants with successful blood collection and analysable cfDNA and EVs
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of enrolled participants for whom blood is successfully collected and both cell-free DNA (cfDNA) and extracellular vesicles (EVs) are successfully isolated and meet prespecified laboratory quality-control criteria for the planned downstream analyses. Feasibility will be assessed at each of the three scheduled blood-collection time points.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of eligible patients who consent to participate
時間枠:At study screening/enrolment.
Percentage of eligible patients with cervical cancer who provide informed consent and enrol in the study among all eligible patients approached for participation.
At study screening/enrolment.
Proportion of cfDNA samples meeting prespecified analytical quality criteria
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of collected plasma samples from which cell-free DNA (cfDNA) is successfully extracted and meets prespecified quality-control criteria for downstream analysis. cfDNA will be quantified and quality assessed, including assessment of yield, integrity, and suitability for planned molecular analyses and/or sequencing.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Proportion of extracellular vesicle samples meeting prespecified analytical quality criteria
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of collected plasma/serum samples from which extracellular vesicles (EVs) are successfully isolated and meet prespecified quality-control criteria for downstream analysis. EV quantity and characteristics will be evaluated using methods including nanoparticle tracking analysis, transmission electron microscopy, and assessment of positive and negative EV markers by western blotting.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Association between baseline cfDNA profiles and cervical cancer stage
時間枠:Baseline
Association between baseline cell-free DNA (cfDNA) characteristics and cervical cancer stage (FIGO stage IA-IVB). Prespecified cfDNA measures and/or molecular signatures obtained from plasma will be evaluated for differences across disease stages. Where applicable, tumour tissue and germline DNA sequencing data will be used as reference controls.
Baseline
Association between baseline extracellular vesicle profiles and cervical cancer stage
時間枠:Baseline
Association between baseline extracellular vesicle (EV) characteristics and cervical cancer stage (FIGO stage IA-IVB). Prespecified EV characteristics, including EV quantity and molecular cargo such as proteins and miRNAs, will be evaluated for differences across disease stages.
Baseline
Association between changes in cfDNA biomarkers and response to radiotherapy or chemoradiotherapy
時間枠:From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between changes in cell-free DNA (cfDNA) biomarkers from baseline to the post-treatment assessment and treatment response among participants receiving radiotherapy or chemoradiotherapy. Treatment response will be determined according to the prespecified clinical and/or radiological response criteria defined in the protocol or statistical analysis plan.
From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between changes in extracellular vesicle biomarkers and response to radiotherapy or chemoradiotherapy
時間枠:From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between changes in extracellular vesicle (EV) characteristics from baseline to the post-treatment assessment and treatment response among participants receiving radiotherapy or chemoradiotherapy. EV characteristics may include quantity and prespecified molecular profiles, including protein and miRNA profiles. Treatment response will be determined using the prespecified clinical and/or radiological response criteria.
From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between cfDNA and EV biomarkers and 24-month disease outcome
時間枠:From baseline through 24 months (±30 days).
Association of baseline and longitudinal cell-free DNA (cfDNA) and extracellular vesicle (EV) biomarker profiles with disease status at 24 months, including recurrence or disease progression as defined in the protocol. Disease status will be determined through review of participants' medical records.
From baseline through 24 months (±30 days).
Completion rate of patient-reported outcome and quality-of-life questionnaires
時間枠:Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of participants who complete the scheduled patient-reported outcome measure (PROM) and quality-of-life (QoL) questionnaires at each assessment time point. Questionnaires include the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), EQ-5D-5L, and lower-extremity lymphoedema questionnaires.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月15日

一次修了 (推定)

2030年9月15日

研究の完了 (推定)

2032年9月15日

試験登録日

最初に提出

2026年8月27日

QC基準を満たした最初の提出物

2026年8月27日

最初の投稿 (実際)

2026年9月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月2日

QC基準を満たした最後の更新が送信されました

2026年8月31日

最終確認日

2026年8月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する